Immunovant, Inc. (IMVT) Halts CLE Program After IMVT-1402 Misses Primary Endpoint
Immunovant said IMVT-1402 did not achieve statistical significance on the primary endpoint in its CLE proof-of-concept study and plans to stop development in CLE. Numerical trends favored IMVT-1402; other autoimmune indications remain in development.Material DetailsContext by AI AnalystThis is an e…